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We read with great interest the article by Lin et al1 in the
Journal of Microbiology, Immunology and Infection in
which they reported that Candida empyema thoracis is a
serious complication of invasive candidiasis and has a high
mortality. The success rate of fluconazole treatment re-
mains uncertain. Candida albicans is the most common
etiology of fungal empyema thoracis. However, the golden
standard treatment for it is controversial. In this paper, we
report a patient who was diagnosed as having nosocomial
Candida empyema thoracis with acute respiratory failure.
He initially received multiple thoracocenteses and flucon-
azole therapy for 14 days, but fever and pleural effusion
persisted (Fig. 1A). He could not be weaned from the
ventilator smoothly. For salvage therapy, we changed from
fluconazole to micafungin (100 mg) intravenous (iv) drip
every 24 hours. Thereafter, he was successfully weaned
from the ventilator. After a 21-day course of micafungin
treatment, chest X-ray imaging revealed an improvement
(Fig. 1B).
The patient, a 91-year-old male, had a history of bladder
adenocarcinoma, stage T4N2M0, status postoperation and
postradiotherapy. He also had chronic obstructive pulmo-
nary disease, coronary artery disease postoperation, and an
old stroke. He was admitted to the hospital because of
fever, dyspnea, and drowsy consciousness. On admission,
laboratory data showed a hemoglobin level of 9.6 mg/dL;
white blood cell count, 17,330 cells/mL; and platelet
count, 214,000 cells/mL. Routine urine examination
revealed pyuria and bacteriuria. The arterial blood gas
showed a pH of 7.175; PaCO2, 17.0 mmHg; PaO2,
76.1 mmHg; and HCO3
, 6.1 mmol/L. He was admitted to
the intensive care unit because of metabolic acidosis, acute
respiratory failure, and urosepsis. During hospitalization,
he received multiple broad-spectrum antibiotic therapies
for the urinary tract infection and ventilator-associated
pneumonia. Sixteen days later, chest X-ray imaging1684-1182/$36 Copyright ª 2014, Taiwan Society of Microbiology. Publ
http://dx.doi.org/10.1016/j.jmii.2013.12.011showed left-sided pleural effusion. Pleural fluid analysis
revealed a lactate dehydrogenase level of 163 U/L (serum,
200 U/L) and a white blood count of 14800/mL with 87%
neutrophils and 13% mononuclear cells. Cultures of the
sputum, pleural fluid, blood, and the tip of the central
venous catheter (CVC) all showed C. albicans. Therefore,
the CVC was removed, and he received fluconazole (800 mg
iv drip stat and 600 mg iv drip every 24 hours) for Candida
empyema thoracis and bloodstream infection. Concurrent
with this treatment, he received multiple thoracocenteses
for drainage. The antifungal agent was replaced by mica-
fungin because of treatment failure with fluconazole. After
a 21-day course of antifungal therapy, the patient was
weaned successfully from the ventilator and micafungin
was discontinued.
Invasive candidiasis has increasingly emerged as an
important hospital-acquired infection, especially in critical
and immunocompromised patients.1e4 The most common
sites of Candida infections are the urinary tract, blood-
stream, and bronchopulmonary system.2 Fungal empyema
thoracis is rare, but its crude mortality is high
(61.9e73%).1e2 Lin et al1 and Ko et al2 report that the most
common fungal isolates recovered from the pleural fluid is
C. albicans, followed by Candida tropicalis, Candida glab-
rata, and Aspergillus species.1e2 The pathogenesis of
Candida empyema thoracis is by contiguous spreading or
noncontiguous spreading to the pleural space.1e4 The most
common underlying disease of Candida empyema thoracis
is a malignancy.1 Many patients acquire it in intensive care
units.2 The reported major causes of fungal empyema
thoracis include previous abdominal surgery, gastrointes-
tinal perforation, bronchopulmonary infections, chest sur-
gery, and bloodstream infections. Our patient’s case may
have resulted from pulmonary Candida infection and CVC-
related candidemia.
Adequate drug penetration into the pleural cavity is
crucial for successful antifungal treatment. Only a fewished by Elsevier Taiwan LLC. All rights reserved.
Figure 1. (A) Chest X-ray reveals cardiomegaly and left side pleural effusion. (B) Chest X-ray shows markedly decreased pleural
effusion after thoracocentesis and micafungin therapy.
460 Correspondencestudies exist regarding the penetration of antifungal agents
into the pleural effusion. Matsuda et al5 used high-
performance liquid chromatography to measure the mica-
fungin and voriconazole concentrations in the plasma and in
the pleural fluid of a patient with fungal empyema thoracis.
They found that the penetration ratio of micafungin was
57e68% and that of voriconazole was 45e95%. The pleural
surface is thicker and more acidic in patients with empy-
ema. Pleural diffusion of antimicrobial agents is highly
variable.6 The concentration of micafungin is high and that
the concentration of micafungin is at a proper therapeutic
level. It also has a greater ability to penetrate the biofilm of
the pleural cavity, compared to fluconazole.5 These two
advantages may contribute to its successful treatment of
fungal empyema.5 For treatment-refractory patients with
Candida empyema thoracis, salvage therapy with mica-
fungin may be an alternative treatment.
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